Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Nuvation Bio (NYSE: NUVB) and has maintained a price target of $11 for the stock.